Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor basket trial) and continued rapid enrollment in ASCEND Orphan drug designations granted for LSTA1 in malignant glioma (U.S.) and …
SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the …
FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended …
LAS VEGAS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG), a leading food distributor to Asian restaurants across the United States (“HF Foods” or the “Company”), today announced it will report financial results for the third quarter …
Phase 1 trial underway for Terns’ first oral GLP-1R agonist candidate for obesity, with 28-day proof of concept data anticipated in 2H24 Oral GLP-1R agonist offers potential for weight loss and improved convenience compared to currently marketed …
Addison, TX, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, …
WESTPORT, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today it has entered into a definitive agreement (the “Agreement”) to sell its majority …
Q3 GAAP EPS of $0.76; Adjusted EPS* of $1.06 Raising Full-Year 2023 Adjusted EPS* Guidance to Range of $4.22-4.32 CHARLOTTE, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SPX Technologies, Inc. (NYSE:SPXC) (“SPX”, the “Company”, “we” or “our”) today reported …
PENNSAUKEN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT) will hold a conference call on Thursday, November 9, 2023 at 11:00 a.m. Eastern time to discuss the financial results for the thirteen and thirty-nine weeks ended …
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on …
KANSAS CITY, Mo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- H&R Block, Inc. (NYSE: HRB) (the “Company”) today announced that its Board of Directors declared a quarterly cash dividend of $0.32 cents per share, payable January 4, 2024, to shareholders of record …
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, …
Earnings Release: Tuesday, November 7, 2023, After Market Closes Conference Call and Webcast: Wednesday, November 8, 2023, at 9:00 A.M. Eastern Time MONACO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the Company) (NYSE: SB), an international …
FREMONT, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor wafer substrates, today reported financial results for the third quarter, ended September 30, 2023. Management Qualitative …
Delivers Strong Operational Results and Raises Annual Guidance Raises Common Equity to Support New Growth Initiatives ATLANTA, GA., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature- …
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Looking Glass Labs Ltd. (“LGL” or the “Company”) (NEO: NFTX) (AQSE: NFTX) (OTC: LGSLF) (FRA: H1N), a leading Web3 platform specializing in non-fungible token (“NFT”) architecture, immersive …
Third quarter sales were $172.1 million, down 1% vs. Q3 2022 Net income was $11.5 million, while net income attributable to DMC was $8.9 million Adjusted net income attributable to DMC* was $9.9 million, up 47% versus Q3 2022 Adjusted diluted EPS …
Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end Cash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: …
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 …
Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study Restructuring plan extends anticipated cash runway into 2026 Company to continue …
02 days 00:54:50
